Viking Therapeutics (VKTX) Enterprise Value (2014 - 2026)
Viking Therapeutics (VKTX) reported Enterprise Value of -$603.0 million for Q1 2026, up 29.22% on a YoY basis from -$466.6 million in Q1 2025, and up 14.56% sequentially from -$705.7 million in Q4 2025.
Viking Therapeutics (VKTX) Enterprise Value (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Enterprise Value data on file, last reported at -$603.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 29.22% year-over-year to -$603.0 million; the trailing twelve-month figure through Mar 2026 stood at -$603.0 million (up 29.22% YoY), and the FY2025 full-year result was -$705.7 million, up 21.81% from the prior year.
- Enterprise Value grew to -$603.0 million in Q1 2026, from -$705.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$135.7 million in Q1 2023 to a low of -$963.0 million in Q1 2024.
- A 5-year average of -$567.9 million and a median of -$603.0 million in 2026 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 61.35% in 2023 and sank 609.82% in 2024, its largest moves.
- Tracing VKTX's Enterprise Value over 5 years: stood at -$155.5 million in 2022, then slumped by 132.87% to -$362.1 million in 2023, then sank by 149.29% to -$902.6 million in 2024, then advanced by 21.81% to -$705.7 million in 2025, then increased by 14.56% to -$603.0 million in 2026.
- Business Quant data shows VKTX's Enterprise Value at -$603.0 million in Q1 2026, -$705.7 million in Q4 2025, and -$714.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -602.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -602.96 Mn |
| Dec 31, 2025 | -705.74 Mn |
| Sep 30, 2025 | -714.57 Mn |
| Jun 30, 2025 | -807.72 Mn |
| Mar 31, 2025 | -851.86 Mn |
| Dec 31, 2024 | -902.61 Mn |
| Sep 30, 2024 | -930.44 Mn |
| Jun 30, 2024 | -942.26 Mn |
| Mar 31, 2024 | -962.98 Mn |
| Dec 31, 2023 | -362.08 Mn |
| Sep 30, 2023 | -376.24 Mn |
| Jun 30, 2023 | -392.92 Mn |
| Mar 31, 2023 | -135.66 Mn |
| Dec 31, 2022 | -155.49 Mn |
| Sep 30, 2022 | -155.02 Mn |
| Jun 30, 2022 | -305.38 Mn |
| Mar 31, 2022 | -351.05 Mn |
| Dec 31, 2021 | -202.10 Mn |
| Sep 30, 2021 | -216.14 Mn |
| Jun 30, 2021 | -228.26 Mn |